
## Megan K Herbert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7946786/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
2	Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, 696-701.	0.5	116
3	Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nature Communications, 2018, 9, 3069.	5.8	116
4	Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nature Communications, 2017, 8, 1000.	5.8	103
5	Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Annals of the Rheumatic Diseases, 2017, 76, 862-868.	0.5	71
6	CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism and Related Disorders, 2014, 20, 112-115.	1.1	70
7	Potential of the Antibody Against <i>cis</i> –Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. JAMA Neurology, 2016, 73, 1356.	4.5	64
8	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Frontiers in Neurology, 2015, 6, 91.	1.1	60
9	Immuneâ€Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	2.9	41
10	Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration. Cell and Bioscience, 2016, 6, 59.	2.1	35
11	Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice. Science Translational Medicine, 2021, 13, .	5.8	34
12	Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Alzheimer's and Dementia, 2014, 10, 448.	0.4	23
13	Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. Journal of Hematology and Oncology, 2018, 11, 73.	6.9	23
14	Novel serology testing for sporadic inclusion body myositis. Current Opinion in Rheumatology, 2015, 27, 595-600.	2.0	22
15	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 832, 114-120.	1.2	17
16	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 605-611.	0.9	17
17	Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. Neurobiology of Aging, 2015, 36, 1271-1273.	1.5	16
18	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 302-309.	1.2	12

Megan K Herbert

#	Article	IF	CITATIONS
19	Limited expression of heparan sulphate proteoglycans associated with AÎ <sup>2</sup> deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease. Neuropathology and Applied Neurobiology, 2010, 36, 478-486.	1.8	11
20	Effect of CYP2D6 metabolizer status on the disposition of the (+) and (â^') enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics, 2007, 17, 305-312.	0.7	10
21	Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. Journal of Neurology, 2013, 260, 3129-3133.	1.8	10
22	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 2008, 65, 347-354.	1.1	7
23	Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. Journal of Immunological Methods, 2012, 381, 1-8.	0.6	4
24	A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example. BBA Clinical, 2015, 4, 1-6.	4.1	2